CAMBRIDGE, Mass., June 13, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome
editing company, today announced that management will participate in two upcoming investor conferences in June. Details are
as follows:
JMP Securities Life Sciences Conference
| Date: |
Tuesday, June 20, 2017 |
| Panel: |
Gene Editing - Pushing the Frontier for Curing Disease |
| Time: |
9:00 a.m. ET |
| Location: |
New York |
Goldman Sachs Third Annual Innovation Symposium
| Date: |
Tuesday, June 27, 2017 |
| Panel: |
CRISPR - The Era of Gene Editing |
| Time: |
10:15 a.m. ET |
| Location: |
New York |
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting
their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the
promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of
patients.
Media Contact Cristi Barnett
Editas Medicine, Inc. (617) 401-0113 cristi.barnett@editasmed.com Investor Contact Mark Mullikin Editas Medicine, Inc. (617) 401-9083 mark.mullikin@editasmed.com
